$1.64
7.34% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
IL0011814113
Symbol
PLRZ
Sector
Industry

Polyrizon Stock price

$1.64
+0.73 80.22% 1M
+0.09 5.81% 6M
+0.09 5.81% YTD
+0.09 5.81% 1Y
+0.09 5.81% 3Y
+0.09 5.81% 5Y
+0.09 5.81% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.13 7.34%
ISIN
IL0011814113
Symbol
PLRZ
Sector
Industry

Key metrics

Market capitalization $6.63m
Enterprise Value $7.01m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-657.00k
Free Cash Flow (TTM) Free Cash Flow $-540.00k
EPS (TTM) EPS $-0.25

Is Polyrizon a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Financial data from Polyrizon

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 0.35 0.35
5% 5%
-
- Research and Development Expense 0.30 0.30
11% 11%
-
-0.65 -0.65
2% 2%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -0.66 -0.66
1% 1%
-
Net Profit -1 -1
163% 163%
-

In millions USD.

Don't miss a Thing! We will send you all news about Polyrizon directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Polyrizon Stock News

Neutral
GlobeNewsWire
10 days ago
Raanana, Israel, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announce today the appointment of Dr. Michal Meir, Senior Consultant at MedTech SME Ltd., as Senior Director of Regulatory and Clinical Affairs. The appointment was made as part of...
Neutral
GlobeNewsWire
11 days ago
The engagement with an EU-based GMP manufacturing facility enables timely production and preparation for clinical trial. The EU-based GMP manufacturer has large-scale commercial production capabilities, to support Polyrizon in future commercialization efforts
Neutral
GlobeNewsWire
16 days ago
Raanana, Israel, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announces today the appointment of Asaf Azulay, the Managing Director of Eurofins' Li-Med team, to its leadership as its VP of Regulatory Affairs and Quality Assurance (RA/QA). Thi...

Company Profile

Polyrizon Ltd. is a development stage biotech company, which engages in the development of nasal hydrogels. It provides barriers from the interaction of biological assaults, including a new strain of coronavirus, influenza, allergens and other airborne pathogens with the nasal epithelial tissue. The company was founded by Tomer Izraeli in January 2005 and is headquartered in Raanana, Israel.

Head office Israel
CEO Tomer Izraeli
Founded 2005
Website polyrizon-biotech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today